Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 13 June, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Lupin Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 13, 2025, 5:56 am

Market Cap 92,399 Cr.
Current Price 2,023
High / Low 2,403/1,531
Stock P/E28.2
Book Value 377
Dividend Yield0.40 %
ROCE21.5 %
ROE20.8 %
Face Value 2.00
PEG Ratio1.29

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lupin Ltd

Competitors of Lupin Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 142 Cr. 101 247/84.327.6 41.70.00 %12.9 %9.75 % 10.0
MPS Pharmaa Ltd 5.27 Cr. 2.76 4.33/2.50 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 41.6 Cr. 56.0 94.9/44.5 8.730.00 %41.5 %14.4 % 10.0
Gujarat Inject (Kerala) Ltd 32.1 Cr. 21.9 29.1/13.131.4 6.830.00 %13.5 %11.0 % 10.0
Industry Average18,999.77 Cr1,191.5892.43194.720.30%16.67%15.20%6.18

All Competitor Stocks of Lupin Ltd

Quarterly Result

MetricMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
Sales 3,8833,7444,1464,3224,4304,8145,0395,1974,9615,6005,6735,7685,667
Expenses 3,6153,5123,6933,7903,8523,9584,1214,1593,9644,3594,3324,4124,346
Operating Profit 2682324535335788569181,0389971,2411,3401,3561,321
OPM % 7%6%11%12%13%18%18%20%20%22%24%24%23%
Other Income 1661518372340292968425457
Interest 41435584938681747168716789
Depreciation 327193203220264235248257457248257271393
Profit before tax -8522102462585596307364989931,0551,071896
Tax % 502%3,925%36%36%6%19%21%16%26%19%19%20%13%
Net Profit -512-87134158242453495619368806859859782
EPS in Rs -11.40-1.962.853.375.199.9410.7613.477.8917.5818.6918.7416.92

Last Updated: May 31, 2025, 8:34 am

Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Sales, as of Mar 2025, the value is 5,667.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,768.00 Cr. (Dec 2024) to 5,667.00 Cr., marking a decrease of 101.00 Cr..
  • For Expenses, as of Mar 2025, the value is 4,346.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4,412.00 Cr. (Dec 2024) to 4,346.00 Cr., marking a decrease of 66.00 Cr..
  • For Operating Profit, as of Mar 2025, the value is 1,321.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,356.00 Cr. (Dec 2024) to 1,321.00 Cr., marking a decrease of 35.00 Cr..
  • For OPM %, as of Mar 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Dec 2024) to 23.00%, marking a decrease of 1.00%.
  • For Other Income, as of Mar 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Dec 2024) to 57.00 Cr., marking an increase of 3.00 Cr..
  • For Interest, as of Mar 2025, the value is 89.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 67.00 Cr. (Dec 2024) to 89.00 Cr., marking an increase of 22.00 Cr..
  • For Depreciation, as of Mar 2025, the value is 393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 271.00 Cr. (Dec 2024) to 393.00 Cr., marking an increase of 122.00 Cr..
  • For Profit before tax, as of Mar 2025, the value is 896.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,071.00 Cr. (Dec 2024) to 896.00 Cr., marking a decrease of 175.00 Cr..
  • For Tax %, as of Mar 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Dec 2024) to 13.00%, marking a decrease of 7.00%.
  • For Net Profit, as of Mar 2025, the value is 782.00 Cr.. The value appears to be declining and may need further review. It has decreased from 859.00 Cr. (Dec 2024) to 782.00 Cr., marking a decrease of 77.00 Cr..
  • For EPS in Rs, as of Mar 2025, the value is 16.92. The value appears to be declining and may need further review. It has decreased from 18.74 (Dec 2024) to 16.92, marking a decrease of 1.82.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:02 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 11,28612,77014,25617,36715,79714,66515,37515,16316,40516,64220,01122,708
Expenses 8,2719,14610,56412,86512,64912,10413,02012,59616,18714,92116,21117,425
Operating Profit 3,0153,6243,6914,5023,1482,5612,3552,5672191,7213,8005,283
OPM % 27%28%26%26%20%17%15%17%1%10%19%23%
Other Income 105235184106-1,31091-134138210151131196
Interest 271059153204302363141143274312295
Depreciation 2614354879121,0868469708871,6598811,1971,169
Profit before tax 2,8323,4153,3293,5435471,5038871,676-1,3727162,4224,015
Tax % 34%28%32%28%53%59%130%27%10%38%20%18%
Net Profit 1,8702,4442,2702,565258615-2701,228-1,5284481,9363,306
EPS in Rs 40.9653.4750.1756.635.5613.40-5.9526.81-33.629.4542.0171.88
Dividend Payout % 15%14%15%13%90%37%-101%24%-12%42%19%17%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)30.70%-7.12%13.00%-89.94%138.37%-143.90%554.81%-224.43%129.32%332.14%70.76%
Change in YoY Net Profit Growth (%)0.00%-37.81%20.12%-102.94%228.31%-282.27%698.72%-779.24%353.75%202.82%-261.38%

Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:6%
5 Years:8%
3 Years:11%
TTM:13%
Compounded Profit Growth
10 Years:3%
5 Years:55%
3 Years:60%
TTM:73%
Stock Price CAGR
10 Years:2%
5 Years:17%
3 Years:49%
1 Year:25%
Return on Equity
10 Years:8%
5 Years:8%
3 Years:13%
Last Year:21%

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 3:09 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 909090909090919191919191
Reserves 6,8428,78411,07313,40713,48713,65212,44613,71212,06212,37414,19917,112
Borrowings 6545377,1787,9667,1438,4966,3055,1294,1584,5422,9225,448
Other Liabilities 2,5503,6423,9574,7495,3005,4235,9684,4985,3405,7946,5396,554
Total Liabilities 10,13513,05422,29826,21226,02027,66124,81023,43021,65122,80023,75129,205
Fixed Assets 3,3564,3688,71711,03310,36211,0877,9387,8817,3828,3558,8789,881
CWIP 3045762,7022,1332,5981,6409401,0661,1461,238773355
Investments 1781,658162,1362622,2952,3742,4559005171,0751,146
Other Assets 6,2976,45110,86210,91012,79812,63913,55712,02812,22412,69013,02617,823
Total Assets 10,13513,05422,29826,21226,02027,66124,81023,43021,65122,80023,75129,205

Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 91.00 Cr..
  • For Reserves, as of Mar 2025, the value is 17,112.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,199.00 Cr. (Mar 2024) to 17,112.00 Cr., marking an increase of 2,913.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 5,448.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,922.00 Cr. (Mar 2024) to 5,448.00 Cr., marking an increase of 2,526.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 6,554.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,539.00 Cr. (Mar 2024) to 6,554.00 Cr., marking an increase of 15.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 29,205.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23,751.00 Cr. (Mar 2024) to 29,205.00 Cr., marking an increase of 5,454.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 9,881.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,878.00 Cr. (Mar 2024) to 9,881.00 Cr., marking an increase of 1,003.00 Cr..
  • For CWIP, as of Mar 2025, the value is 355.00 Cr.. The value appears to be declining and may need further review. It has decreased from 773.00 Cr. (Mar 2024) to 355.00 Cr., marking a decrease of 418.00 Cr..
  • For Investments, as of Mar 2025, the value is 1,146.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,075.00 Cr. (Mar 2024) to 1,146.00 Cr., marking an increase of 71.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 17,823.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,026.00 Cr. (Mar 2024) to 17,823.00 Cr., marking an increase of 4,797.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 29,205.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,751.00 Cr. (Mar 2024) to 29,205.00 Cr., marking an increase of 5,454.00 Cr..

Notably, the Reserves (17,112.00 Cr.) exceed the Borrowings (5,448.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-651.00-534.00-4.00-3.00-4.00-6.00-4.00-3.00215.00-3.001.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days83807611691120128129108959886
Inventory Days200204220276266253283232279261242272
Days Payable159152172168189178184162137129136163
Cash Conversion Cycle125131124225167195227199249227204195
Working Capital Days92946714711213715492151135127103
ROCE %33%41%40%24%19%10%10%9%9%-7%6%16%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters46.78%47.10%47.11%47.10%47.08%47.07%47.06%47.04%47.01%46.99%46.96%46.94%
FIIs14.65%14.27%13.81%13.98%13.32%13.93%14.99%16.11%18.29%19.32%21.50%22.04%
DIIs26.91%26.89%27.63%29.39%28.92%29.08%29.14%29.72%27.76%26.77%25.10%24.73%
Government0.29%0.29%0.00%0.00%0.28%0.28%0.28%0.01%0.01%0.01%0.01%0.01%
Public11.37%11.45%11.45%9.51%10.39%9.62%8.52%7.10%6.93%6.92%6.44%6.27%
No. of Shareholders3,78,5473,82,8283,78,0113,60,6773,48,1493,22,6782,89,0742,81,5422,80,2482,88,5372,79,2802,81,988

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Balanced Advantage Fund - Regular Plan 5,852,165 1.03 660.215,852,1652025-04-22 17:25:280%
ICICI Prudential Bluechip Fund 5,051,556 1.38 569.895,051,5562025-04-22 17:25:280%
ICICI Prudential Value Discovery Fund 4,451,818 1.55 502.234,451,8182025-04-22 17:25:280%
HDFC Flexi Cap Fund - Regular Plan 4,250,000 1.22 479.464,250,0002025-04-22 17:25:280%
Mirae Asset Emerging Bluechip Fund 4,055,585 1.63 457.534,055,5852025-04-22 17:25:280%
HDFC Top 100 Fund - Regular Plan 3,369,013 1.47 380.083,369,0132025-04-22 12:29:180%
Mirae Asset Midcap Fund 2,934,086 2.81 331.012,934,0862025-04-22 17:25:280%
SBI Long Term Equity Fund 2,687,887 1.92 303.232,687,8872025-04-22 17:25:280%
ICICI Prudential Multi Asset Fund 2,004,292 0.91 226.112,004,2922025-04-22 17:25:280%
ICICI Prudential Large & Mid Cap Fund 1,584,850 2.02 178.791,584,8502025-04-22 17:25:280%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 42.059.46-33.6526.84-5.95
Diluted EPS (Rs.) 41.879.41-33.6526.72-5.95
Cash EPS (Rs.) 68.7429.203.2846.5915.38
Book Value[Excl.RevalReserv]/Share (Rs.) 315.41275.67268.91305.45277.73
Book Value[Incl.RevalReserv]/Share (Rs.) 315.41275.67268.91305.45277.73
Revenue From Operations / Share (Rs.) 439.12365.75360.96334.21339.40
PBDIT / Share (Rs.) 86.2641.139.4459.5862.66
PBIT / Share (Rs.) 59.9921.78-27.0640.0241.24
PBT / Share (Rs.) 53.1515.75-30.2036.9216.63
Net Profit / Share (Rs.) 42.479.84-33.2227.04-6.04
NP After MI And SOA / Share (Rs.) 42.019.45-33.6226.81-5.95
PBDIT Margin (%) 19.6411.242.6117.8218.46
PBIT Margin (%) 13.665.95-7.4911.9712.15
PBT Margin (%) 12.104.30-8.3611.044.89
Net Profit Margin (%) 9.672.69-9.208.08-1.78
NP After MI And SOA Margin (%) 9.562.58-9.318.02-1.75
Return on Networth / Equity (%) 13.393.45-12.578.81-2.14
Return on Capital Employeed (%) 17.647.23-9.0711.9611.85
Return On Assets (%) 7.971.87-7.005.15-1.07
Long Term Debt / Equity (X) 0.000.000.010.000.14
Total Debt / Equity (X) 0.180.340.310.220.34
Asset Turnover Ratio (%) 0.850.500.510.470.45
Current Ratio (X) 1.581.341.511.661.67
Quick Ratio (X) 0.990.850.941.171.30
Inventory Turnover Ratio (X) 0.870.820.770.880.87
Dividend Payout Ratio (NP) (%) 9.5042.28-19.3122.34-84.00
Dividend Payout Ratio (CP) (%) 5.8513.87225.8212.9232.29
Earning Retention Ratio (%) 90.5057.72119.3177.66184.00
Cash Earning Retention Ratio (%) 94.1586.13-125.8287.0867.71
Interest Coverage Ratio (X) 12.616.823.0019.227.82
Interest Coverage Ratio (Post Tax) (X) 7.212.63-9.579.721.96
Enterprise Value (Cr.) 75275.9532506.4236722.7147698.5728589.60
EV / Net Operating Revenue (X) 3.761.952.243.151.86
EV / EBITDA (X) 19.1517.3785.6217.6510.07
MarketCap / Net Operating Revenue (X) 3.681.772.073.051.74
Retention Ratios (%) 90.4957.71119.3177.65184.00
Price / BV (X) 5.162.362.793.362.13
Price / Net Operating Revenue (X) 3.681.772.073.051.74
EarningsYield 0.020.01-0.040.02-0.01

After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 42.05. This value is within the healthy range. It has increased from 9.46 (Mar 23) to 42.05, marking an increase of 32.59.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 41.87. This value is within the healthy range. It has increased from 9.41 (Mar 23) to 41.87, marking an increase of 32.46.
  • For Cash EPS (Rs.), as of Mar 24, the value is 68.74. This value is within the healthy range. It has increased from 29.20 (Mar 23) to 68.74, marking an increase of 39.54.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 315.41. It has increased from 275.67 (Mar 23) to 315.41, marking an increase of 39.74.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 315.41. It has increased from 275.67 (Mar 23) to 315.41, marking an increase of 39.74.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 439.12. It has increased from 365.75 (Mar 23) to 439.12, marking an increase of 73.37.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 86.26. This value is within the healthy range. It has increased from 41.13 (Mar 23) to 86.26, marking an increase of 45.13.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 59.99. This value is within the healthy range. It has increased from 21.78 (Mar 23) to 59.99, marking an increase of 38.21.
  • For PBT / Share (Rs.), as of Mar 24, the value is 53.15. This value is within the healthy range. It has increased from 15.75 (Mar 23) to 53.15, marking an increase of 37.40.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 42.47. This value is within the healthy range. It has increased from 9.84 (Mar 23) to 42.47, marking an increase of 32.63.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 42.01. This value is within the healthy range. It has increased from 9.45 (Mar 23) to 42.01, marking an increase of 32.56.
  • For PBDIT Margin (%), as of Mar 24, the value is 19.64. This value is within the healthy range. It has increased from 11.24 (Mar 23) to 19.64, marking an increase of 8.40.
  • For PBIT Margin (%), as of Mar 24, the value is 13.66. This value is within the healthy range. It has increased from 5.95 (Mar 23) to 13.66, marking an increase of 7.71.
  • For PBT Margin (%), as of Mar 24, the value is 12.10. This value is within the healthy range. It has increased from 4.30 (Mar 23) to 12.10, marking an increase of 7.80.
  • For Net Profit Margin (%), as of Mar 24, the value is 9.67. This value is within the healthy range. It has increased from 2.69 (Mar 23) to 9.67, marking an increase of 6.98.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.56. This value is within the healthy range. It has increased from 2.58 (Mar 23) to 9.56, marking an increase of 6.98.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 13.39. This value is below the healthy minimum of 15. It has increased from 3.45 (Mar 23) to 13.39, marking an increase of 9.94.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 17.64. This value is within the healthy range. It has increased from 7.23 (Mar 23) to 17.64, marking an increase of 10.41.
  • For Return On Assets (%), as of Mar 24, the value is 7.97. This value is within the healthy range. It has increased from 1.87 (Mar 23) to 7.97, marking an increase of 6.10.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.18. This value is within the healthy range. It has decreased from 0.34 (Mar 23) to 0.18, marking a decrease of 0.16.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.85. It has increased from 0.50 (Mar 23) to 0.85, marking an increase of 0.35.
  • For Current Ratio (X), as of Mar 24, the value is 1.58. This value is within the healthy range. It has increased from 1.34 (Mar 23) to 1.58, marking an increase of 0.24.
  • For Quick Ratio (X), as of Mar 24, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.85 (Mar 23) to 0.99, marking an increase of 0.14.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.87. This value is below the healthy minimum of 4. It has increased from 0.82 (Mar 23) to 0.87, marking an increase of 0.05.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 9.50. This value is below the healthy minimum of 20. It has decreased from 42.28 (Mar 23) to 9.50, marking a decrease of 32.78.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.85. This value is below the healthy minimum of 20. It has decreased from 13.87 (Mar 23) to 5.85, marking a decrease of 8.02.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 90.50. This value exceeds the healthy maximum of 70. It has increased from 57.72 (Mar 23) to 90.50, marking an increase of 32.78.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.15. This value exceeds the healthy maximum of 70. It has increased from 86.13 (Mar 23) to 94.15, marking an increase of 8.02.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 12.61. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 12.61, marking an increase of 5.79.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 7.21. This value is within the healthy range. It has increased from 2.63 (Mar 23) to 7.21, marking an increase of 4.58.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 75,275.95. It has increased from 32,506.42 (Mar 23) to 75,275.95, marking an increase of 42,769.53.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.76. This value exceeds the healthy maximum of 3. It has increased from 1.95 (Mar 23) to 3.76, marking an increase of 1.81.
  • For EV / EBITDA (X), as of Mar 24, the value is 19.15. This value exceeds the healthy maximum of 15. It has increased from 17.37 (Mar 23) to 19.15, marking an increase of 1.78.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.68. This value exceeds the healthy maximum of 3. It has increased from 1.77 (Mar 23) to 3.68, marking an increase of 1.91.
  • For Retention Ratios (%), as of Mar 24, the value is 90.49. This value exceeds the healthy maximum of 70. It has increased from 57.71 (Mar 23) to 90.49, marking an increase of 32.78.
  • For Price / BV (X), as of Mar 24, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 23) to 5.16, marking an increase of 2.80.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.68. This value exceeds the healthy maximum of 3. It has increased from 1.77 (Mar 23) to 3.68, marking an increase of 1.91.
  • For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Lupin Ltd as of June 13, 2025 is: 1,776.14

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 13, 2025, Lupin Ltd is Overvalued by 12.20% compared to the current share price 2,023.00

Intrinsic Value of Lupin Ltd as of June 13, 2025 is: 2,163.41

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 13, 2025, Lupin Ltd is Undervalued by 6.94% compared to the current share price 2,023.00

Last 5 Year EPS CAGR: 21.80%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 17.50%, which is a positive sign.
  2. The company has higher reserves (12,429.17 cr) compared to borrowings (5,039.83 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (15.58 cr) and profit (180.67 cr) over the years.
  1. The stock has a high average Working Capital Days of 117.58, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 189.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
    1. Net Profit Margin: 9.67%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 17.64% (Industry Average ROCE: 16.67%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 13.39% (Industry Average ROE: 15.2%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.21
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.99
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 28.2 (Industry average Stock P/E: 92.43)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.18
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 16967.50 Cr. and Equity Capital is Rs. 91.32 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsKalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055info@lupin.com
http://www.lupin.com
Management
NamePosition Held
Mrs. Manju D GuptaChairman
Mr. Nilesh D GuptaManaging Director
Ms. Vinita GuptaDirector & CEO
Mr. Ramesh SwaminathanExecutive Director & Global CFO
Mr. Mark D McDadeIndependent Director
Dr. Punita Kumar-SinhaIndependent Director
Mr. Jean-Luc BelingardIndependent Director
Mr. Jeffrey KindlerIndependent Director
Mr. Alfonso ZuluetaIndependent Director

FAQ

What is the intrinsic value of Lupin Ltd?

Lupin Ltd's intrinsic value (as of 13 June 2025) is ₹1776.14 — 12.20% lower the current market price of 2,023.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 92,399 Cr. market cap, FY2025-2026 high/low of ₹2,403/1,531, reserves of 17,112 Cr, and liabilities of 29,205 Cr.

What is the Market Cap of Lupin Ltd?

The Market Cap of Lupin Ltd is 92,399 Cr..

What is the current Stock Price of Lupin Ltd as on 13 June 2025?

The current stock price of Lupin Ltd as on 13 June 2025 is 2,023.

What is the High / Low of Lupin Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Lupin Ltd stocks is ₹2,403/1,531.

What is the Stock P/E of Lupin Ltd?

The Stock P/E of Lupin Ltd is 28.2.

What is the Book Value of Lupin Ltd?

The Book Value of Lupin Ltd is 377.

What is the Dividend Yield of Lupin Ltd?

The Dividend Yield of Lupin Ltd is 0.40 %.

What is the ROCE of Lupin Ltd?

The ROCE of Lupin Ltd is 21.5 %.

What is the ROE of Lupin Ltd?

The ROE of Lupin Ltd is 20.8 %.

What is the Face Value of Lupin Ltd?

The Face Value of Lupin Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lupin Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE